| (Values in U.S. Thousands) | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
| Sales | 1,280,000 | 1,196,000 | 1,216,000 | 1,099,000 | 1,173,000 |
| Sales Growth | +7.02% | -1.64% | +10.65% | -6.31% | +16.48% |
| Net Income | -3,000 | 4,000 | -151,000 | -167,000 | -54,000 |
| Net Income Growth | -175.00% | +102.65% | +9.58% | -209.26% | +35.71% |
Bausch & Lomb Corp (BLCO)
13.88 x 1 14.15 x 35
Post-market by (Cboe BZX)
14.13 -0.87 (-5.80%) 03/28/25 [NYSE]
13.88 x 1 14.15 x 35
Post-market 14.15 +0.02 (+0.14%) 19:57 ET
for Fri, Mar 28th, 2025
Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R). Bausch Lomb Corporation is based in VAUGHAN, ON.
Fiscal Year End Date: 12/31